10:39 AM EST - Aptose Biosciences Inc. : Announced an exclusive global license agreement that provides OHM Oncology (“OHM”) with the rights for the development, manufacture and commercialization of APL-581, as well as related molecules from Aptose’s dual bromodomain and extra-terminal domain motif (BET) protein and kinase inhibitor program. Aptose will retain reacquisition rights to certain molecules, while OHM will have the rights to develop and sublicense all other molecules. Aptose Biosciences Inc.
shares T.APS are trading up $0.04 at $4.12.
